2026 Summer Intern PhD Student - Materials Characterization/Process Analytical Technologies at Bristol-Myers Squibb

New Brunswick, New Jersey, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

PharmaceuticalIndustries

Requirements

Currently enrolled in an accredited university program seeking a Ph.D. in Analytical Chemistry, Chemical Engineering, Physical Chemistry, Materials Science, Pharmaceutical Sciences, Physics, or a related field, with a focus on relevant areas
Experience in one or more of the following: Materials Characterization, Spectroscopy (Raman, NIR, IR), X-Ray diffraction, Process Analytical Technologies
Strong understanding of spectroscopic techniques
Highly motivated and self-driven
Demonstrated innovative problem-solving abilities
Ability to work both independently and collaboratively in a team environment

Responsibilities

Develop methods for product characterization
Develop and implement PAT methods to monitor and control pharmaceutical processes
Design and execute experiments to evaluate PAT tools and develop and validate methods
Collaborate with multi-disciplinary teams, including formulation scientists, analytical chemists, process engineers, and process modelers, to enable drug product formulation development and manufacturing processes
Troubleshoot and resolve issues related to characterization and PAT methodologies
Work with mentors for ~10 weeks on a guided research project within a PD Project Team

Skills

Materials Characterization

Vibrational Spectroscopy

X-ray Diffraction

Raman

NIR

Process Analytical Technologies

PAT

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free